血必净联合胸腺肽α1治疗重症肺炎合并脓毒症的效果

The Effect of Xuebijing Combined with Thymosin α1 in the Treatment of Severe Pneumonia Complicated with Sepsis

目的观察血必净联合胸腺肽α1用于重症肺炎合并脓毒症的治疗效果。方法选取2018年2月~2019年8月在我院治疗的47例重症肺炎合并脓毒症患者为研究对象,采用随机数字表法分为对照组(n=24)和观察组(n=23)。对照组采用血必净治疗,观察组在对照组基础上联合胸腺肽α1治疗,比较两组临床治疗总有效率、细菌清除率、治疗前后呼吸、心率、炎症指标[白细胞计数(WBC)、血清白细胞介素-6(IL-6)、血清肿瘤坏死因子α(TNF-α)、血清前降钙素(PCT)、C反应蛋白(CRP)]、血气指标[二氧化碳分压(PaCO2)、动脉血氧分压(PaO2)]及不良反应发生情况。结果观察组治疗总有效率为91.30%,高于对照组的79.16%,差异有统计学意义(P<0.05);观察组细菌清除率为82.61%,高于对照组的70.83%,差异有统计学意义(P<0.05);治疗后两组WBC、IL-6、TNF-α、PCT、CRP均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后两组后PaCO2水平低于治疗前,PaO2水平高于治疗前,且观察组PaCO2水平低于对照组,PaO2水平高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为13.04%,与对照组的12.50%比较,差异无统计学意义(P>0.05)。结论重症肺炎合并脓毒症采用血必净联合胸腺肽α1治疗有效率和细菌清除率高,炎症减轻,血气改善,且临床不良反应少,应用安全可靠。

Objective To observe the therapeutic effect of Xuebijing combined with thymosinα1 for severe pneumonia combined with sepsis.Methods 47 patients with severe pneumonia combined with sepsis who were treated in our hospital from February 2018 to August 2019 were selected as the research objects.They were divided into the control group(n=24)and the observation group(n=23)by random number table method.The control group was treated with Xuebijing,and the observation group was treated with thymosinα1 on the basis of the control group.The total effective rate of clinical treatment,bacterial clearance,respiration,heart rate,and inflammation indicators[white blood cell count(WBC),serum white blood cell Interleukin-6(IL-6),serum tumor necrosis factor alpha(TNF-α),serum procalcitonin(PCT),C-reactive protein(CRP)],blood gas indicators[partial pressure of carbon dioxide(PaCO2),arterial blood Partial pressure of oxygen(PaO2)]and the occurrence of adverse reactions.Results The total effective rate of treatment in the observation group was 91.30%,which was higher than 79.16% in the control group,the difference was statistically significant(P<0.05);the bacterial clearance rate in the observation group was 82.61%,which was higher than 70.83% in the control group,the difference was statistically significant(P<0.05);WBC,IL-6,TNF-α,PCT and CRP in the two groups after treatment were lower than those before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05);The PaCO2 level after the latter two groups was lower than before treatment,the PaO2 level was higher than before treatment,and the PaCO2 level of the observation group was lower than that of the control group,and the PaO2 level was higher than that of the control group,the difference was statistically significant(P<0.05);adverse reactions in the observation group the incidence rate was 13.04%,compared with 12.50% in the control group,the difference was not statistically significant(P>0.05).Conclusion Xuebijing combined with thymosinα1 for severe pneumonia combined with sepsis has a high effective rate and high bacterial clearance rate,reduced inflammation,improved blood gas,and few clinical adverse reactions.The application is safe and reliable.